Showing 1765 results
-
Press release /JDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor, shows 57% confirmed ORR at recommended dose of 200 mg twice daily in Phase Ib study in patients with…
-
Press release /In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement…
-
Press release /Findings across six countries and four continents showed a reduction in quality of life for majority (71%) of patients living with myeloproliferative neoplasms (MPNs)[1] Patients…
-
Press release /Phase II study met primary endpoint, demonstrating promising visual acuity gains in patients with neovascular (wet) age-related macular degeneration Data shows the potential for less…
-
Press release /Les actionnaires approuvent la 22e hausse consécutive du dividende à CHF 2.85 (+2%) par action pour 2018, soit un rendement de 3,1% et une distribution du free cash-flow d'environ 57% Une…
-
Press release /Updated iptacopan data confirm hemolysis control in paroxysmal nocturnal hemoglobinuria (PNH) patients from Phase III APPLY-PNH and APPOINT-PNH studies Head-to-head data from Phase III…
-
Press release /Les actionnaires approuvent la 21e hausse consécutive du dividende, à CHF 2,80 (+2 %) par action au titre de l'exercice 2017, soit un rendement de 3,6 % et une distribution du free cash-…
-
Press release /Huntington’s disease is a rare, inherited neurodegenerative disease that leads to progressive disability and deathThere are no approved disease modifying therapies that delay disease onset or slow…
-
Press release /New approvals are based on JUNIPERA trial data showing Cosentyx® (secukinumab) demonstrated reduced flare risk versus placebo and improvement in disease activity observed over two years across both…